Gero

Thanks @Nasdaq for celebrating our recent partnership with @chugai_cc to develop novel therapies for age-related diseases. 🧬🧬 Read the news: shorturl.at/JZAck

💻 Read more about our latest strides in citybiz: citybiz.co/article/861600…

Unlike other longevity-focused biotechnology companies, our approach at Gero is centered on slowing the biological processes underlying aging. ✔️ Our models are designed to distinguish between reversible disease mechanisms, helping to identify therapeutic targets. 🧬

💻 Learn more about what’s next for Gero in @pulse2news: pulse2.com/gero-raises-17…

Our recent funding round at Gero will support the preclinical development of our pipeline and expand our pharmaceutical partnerships. 🧬 Now, we can further develop our breakthrough medicines designed to slow aging, treat age-related diseases, and extend functional lifespan.

Learn more about ProtoBind: globenewswire.com/news-release/2…

👏 Learn more about this honor: #nominees" target="_blank" rel="nofollow noopener">nebius.com/ai-discovery-a…

The @nebiusai Discovery Awards 2026 were a success. 🏆 We’re thrilled to share that Gero earned an Honorable Mention for our ProtoBind platform, a generative AI model for small-molecule design directly from protein sequence, placing among the top 10 projects in our category.

📺 Our Co-founder and CEO, @fedichev, shared more about our mission with @MHealthspan: youtu.be/NU8RAZhQhT4?si…

The harsh truth. ⬇️ Despite improving health and lifestyle choices, people are not getting younger. 👀 Aging is a physics problem that molecular biology alone cannot answer, and that’s exactly what we’re working to solve at Gero.

We’re thrilled to announce that Eileen Brandenburger has joined Gero as our new Head of Intellectual Property and Licensing! 🧬 In her role at Gero, she’ll lead our commercial and technical IP legal work, drawing on her expertise in the field. Welcome to the team, Eileen.

🧬 Learn more about our latest step in revolutionizing the aging process: businesswire.com/news/home/2026…

We’re accelerating at Gero from a discovery engine to a preclinical-stage drug developer. 👏 By reaching $34M in total funding, including a new $17M round to advance the preclinical pipeline in age-related diseases, we’re on track to pioneer a new class of medicines.

@wef This World Economic Forum recognition is validation that the approach we’ve taken is starting to gain broader traction. Happy to be part of the 2026 cohort.

@wef We’ve been working at the intersection of theoretical #physics, large-scale human data, and machine learning to model #aging as a complex dynamical system — specifically, the progressive loss of resilience and the accumulation of irreversible damage that drives disease.

Gero has been named a 2026 Technology Pioneer by the World Economic Forum (@wef). Read the full announcement: businesswire.com/news/home/2026…

We're taking the smarter approach: halt aging before the disease develops. By intercepting functional decline early, we extend the years that actually matter—the healthy ones. That's longevity: a dramatically longer healthspan. The future is bright. 👏

We approach #lifespan differently at Gero. 🧬 Young people don't get Alzheimer's or cancer. Chronic disease is an aging problem. Modern medicine treats the disease after it arrives—but we can't really cure most of them.

We’re thrilled to be part of the conversation and to continue driving positive change within the industry to support functional #lifespan.

GLP-1's impact on weight loss and metabolic fitness has spurred efforts to develop novel interventions targeting multiple pathways to promote healthy longevity. However, many nutritional and fitness approaches discussed still aren’t effectively enhancing #longevity.​ 📊

Future Fit Asia 2026 was a success! 👏 Our R&D Director, Michael Winther, represented Gero and joined a panel to discuss current practices that go beyond #GLP-1 therapies to advance #metabolic health. His main takeaway. ⬇️